Publications 2022

Bruni C, Heidenreich S, Duenas A, Hoffmann-Vold AM, Gabrielli A, Allanore Y, Chatelus E, Distler JHW, Hachulla E, Hsu VM, Hunzelmann N, Khanna D, Truchetet ME, Walker UA, Alves M, Schoof N, Saketkoo LA, Distler O (2022)
Patient preferences for the treatment of systemic sclerosis-associated interstitial lung disease: a discrete choice experiment
Rheumatology (Oxford) (in press)
DOI 10.1093/rheumatology/keac126, PubMed 35238334

Hilberg O, Hoffmann-Vold AM, Smith V, Bouros D, Kilpeläinen M, Guiot J, Morais A, Clemente S, Daniil Z, Papakosta D, Fretheim H, Neves S, Alfaro TM, Antoniou KM, Valveny N, Asijee G, Soulard S, Wuyts W (2022)
Epidemiology of interstitial lung diseases and their progressive-fibrosing behaviour in six European countries
ERJ Open Res, 8 (1)
DOI 10.1183/23120541.00597-2021, PubMed 35083316

Iudici M, Jarlborg M, Lauper K, Müller-Ladner U, Smith V, Allanore Y, Balbir-Gurman A, Doria A, Airò P, Walker UA, Riccieri V, Vonk MC, Gabrielli A, Hoffmann-Vold AM, Szücs G, Martin T, Distler O, Courvoisier DS, EUSTAR collaborators (2022)
Representativeness of systemic sclerosis patients in interventional randomized trials: an analysis of the EUSTAR database
Rheumatology (Oxford), 61 (2), 743-755
DOI 10.1093/rheumatology/keab437, PubMed 33989387

Matteson EL, Kelly C, Distler JHW, Hoffmann-Vold AM, Seibold JR, Mittoo S, Dellaripa PF, Aringer M, Pope J, Distler O, James A, Schlenker-Herceg R, Stowasser S, Quaresma M, Flaherty KR, INBUILD Trial Investigators (2022)
Nintedanib in Patients With Autoimmune Disease-Related Progressive Fibrosing Interstitial Lung Diseases: Subgroup Analysis of the INBUILD Trial
Arthritis Rheumatol (in press)
DOI 10.1002/art.42075, PubMed 35199968

Schniering J, Maciukiewicz M, Gabrys HS, Brunner M, Blüthgen C, Meier C, Braga-Lagache S, Uldry AC, Heller M, Guckenberger M, Fretheim H, Nakas CT, Hoffmann-Vold AM, Distler O, Frauenfelder T, Tanadini-Lang S, Maurer B (2022)
Computed tomography-based radiomics decodes prognostic and molecular differences in interstitial lung disease related to systemic sclerosis
Eur Respir J, 59 (5)
DOI 10.1183/13993003.04503-2020, PubMed 34649979

Solomon JJ, Swigris JJ, Kreuter M, Polke M, Aronson K, Hoffmann-Vold AM, Dellaripa PF (2022)
The attitudes and practices of physicians caring for patients with rheumatoid arthritis-associated interstitial lung disease: an international survey
Rheumatology (Oxford), 61 (4), 1459-1467
DOI 10.1093/rheumatology/keab552, PubMed 34260687

Tennøe AH, Murbræch K, Didriksen H, Ueland T, Palchevskiy V, Weigt SS, Fretheim H, Midtvedt Ø, Garen T, Brunborg C, Aukrust P, Molberg Ø, Belperio JA, Hoffmann-Vold AM (2022)
Serum markers of cardiac complications in a systemic sclerosis cohort
Sci Rep, 12 (1), 4661
DOI 10.1038/s41598-022-08815-8, PubMed 35304587

Volkmann ER, Kreuter M, Hoffmann-Vold AM, Wijsenbeek M, Smith V, Khanna D, Denton CP, Wuyts WA, Miede C, Alves M, Sambevski S, Allanore Y, SENSCIS trial investigators (2022)
Dyspnoea and cough in patients with systemic sclerosis-associated interstitial lung disease in the SENSCIS trial
Rheumatology (Oxford) (in press)
DOI 10.1093/rheumatology/keac091, PubMed 35150246

Zanatta E, Huscher D, Ortolan A, Avouac J, Airò P, Balbir-Gurman A, Siegert E, Cerinic MM, Cozzi F, Riemekasten G, Hoffmann-Vold AM, Distler O, Gabrielli A, Heitmann S, Hunzelmann N, Montecucco C, Morovic-Vergles J, Ribi C, Doria A, Allanore Y, (2022)
Phenotype of limited cutaneous systemic sclerosis patients with positive anti-topoisomerase I antibodies: data from EUSTAR cohort
Rheumatology (Oxford) (in press)
DOI 10.1093/rheumatology/keac188, PubMed 35348643

Publications 2021

Buschulte K, Hoffmann-Vold AM, Dobrota RD, Höger P, Krause A, Kreuter M (2021)
[Treatment of lung fibrosis in systemic rheumatic diseases (new treatment)]
Z Rheumatol, 80 (8), 743-754
DOI 10.1007/s00393-021-01067-3, PubMed 34505934

Didriksen H, Molberg Ø, Fretheim H, Gude E, Jordan S, Brunborg C, Palchevskiy V, Garen T, Midtvedt Ø, Andreassen AK, Distler O, Belperio J, Hoffmann-Vold AM (2021)
Association of Lymphangiogenic Factors With Pulmonary Arterial Hypertension in Systemic Sclerosis
Arthritis Rheumatol, 73 (7), 1277-1287
DOI 10.1002/art.41665, PubMed 33497027

Dobrota R, Jordan S, Juhl P, Maurer B, Wildi L, Bay-Jensen AC, Karsdal MA, Herrick AL, Distler JHW, Allanore Y, Hoffmann-Vold AM, Siebuhr AS, Distler O (2021)
Circulating collagen neo-epitopes and their role in the prediction of fibrosis in patients with systemic sclerosis: a multicentre cohort study
Lancet Rheumatol., 3 (3), E175-E184
DOI 10.1016/S2665-9913(20)30385-4

Gigante A, Hoffmann-Vold AM, Alunni Fegatelli D, Gabrielli A, Leodori G, Coleiro B, De Santis M, Dagna L, Alegre-Sancho JJ, Montecucco C, Carreira PE, Balbir-Gurman A, Doria A, Riemekasten G, Airò P, Distler J, Distler O, Rosato E, EUSTAR collaborators (2021)
Estimated glomerular filtration rate is a marker of mortality in the European Scleroderma Trials and Research Group (EUSTAR) database
Rheumatology (Oxford), 61 (1), 213-222
DOI 10.1093/rheumatology/keab302, PubMed 33769468

Highland KB, Distler O, Kuwana M, Allanore Y, Assassi S, Azuma A, Bourdin A, Denton CP, Distler JHW, Hoffmann-Vold AM, Khanna D, Mayes MD, Raghu G, Vonk MC, Gahlemann M, Clerisme-Beaty E, Girard M, Stowasser S, Zoz D, Maher TM, SENSCIS trial investigators (2021)
Efficacy and safety of nintedanib in patients with systemic sclerosis-associated interstitial lung disease treated with mycophenolate: a subgroup analysis of the SENSCIS trial
Lancet Respir Med, 9 (1), 96-106
DOI 10.1016/S2213-2600(20)30330-1, PubMed 33412120

Hoffmann-Vold AM, Bendstrup E, Dimitroulas T, Hesselstrand R, Morais A, Peltomaa R, Smith V, Welling J, Vonk MC, Wuyts WA (2021)
Identifying unmet needs in SSc-ILD by semi-qualitative in-depth interviews
Rheumatology (Oxford), 60 (12), 5601-5609
DOI 10.1093/rheumatology/keab154, PubMed 33587103

Hoffmann-Vold AM, Fretheim HH, Sarna VK, Barua I, Carstens MN, Distler O, Khanna D, Volkmann ER, Midtvedt Ø, Didriksen H, Dhainaut A, Halse AK, Bakland G, Pesonen M, Olsen I, Molberg Ø (2021)
Safety and efficacy of faecal microbiota transplantation by Anaerobic Cultivated Human Intestinal Microbiome (ACHIM) in patients with systemic sclerosis: study protocol for the randomised controlled phase II ReSScue trial
BMJ Open, 11 (6), e048541
DOI 10.1136/bmjopen-2020-048541, PubMed 34168032

Hoffmann-Vold AM, Kreuter M (2021)
One-step closer to solve the mystery of predicting disease progression in systemic sclerosis associated interstitial lung disease?
Thorax, 76 (12), 1170-1171
DOI 10.1136/thoraxjnl-2021-217811, PubMed 34446525

Hoffmann-Vold AM, Maher TM, Philpot EE, Ashrafzadeh A, Distler O (2021)
Assessment of recent evidence for the management of patients with systemic sclerosis-associated interstitial lung disease: a systematic review
ERJ Open Res, 7 (1)
DOI 10.1183/23120541.00235-2020, PubMed 33644224

Kreuter M, Hoffmann-Vold AM, Bendstrup E (2021)
Interstitial lung diseases: quo vadis?
Lancet Respir Med, 9 (10), 1084-1087
DOI 10.1016/S2213-2600(21)00403-3, PubMed 34499873

Panagopoulos P, Goules A, Hoffmann-Vold AM, Matteson EL, Tzioufas A (2021)
Natural history and screening of interstitial lung disease in systemic autoimmune rheumatic disorders
Ther Adv Musculoskelet Dis, 13, 1759720X211037519
DOI 10.1177/1759720X211037519, PubMed 34471427

van Leeuwen NM, Boonstra M, Bakker JA, Grummels A, Jordan S, Liem S, Distler O, Hoffmann-Vold AM, Melsens K, Smith V, Truchetet ME, Scherer HU, Toes R, Huizinga TWJ, de Vries-Bouwstra JK (2021)
Anticentromere Antibody Levels and Isotypes and the Development of Systemic Sclerosis
Arthritis Rheumatol, 73 (12), 2338-2347
DOI 10.1002/art.41814, PubMed 34042326

Wang Y, Chen S, Zheng S, Lin J, Hu S, Zhuang J, Lin Q, Xie X, Zheng K, Zhang W, Du G, Zhang G, Hoffmann-Vold AM, Matucci-Cerinic M, Furst DE (2021)
The role of lung ultrasound B-lines and serum KL-6 in the screening and follow-up of rheumatoid arthritis patients for an identification of interstitial lung disease: review of the literature, proposal for a preliminary algorithm, and clinical application to cases
Arthritis Res Ther, 23 (1), 212
DOI 10.1186/s13075-021-02586-9, PubMed 34391465

Publications 2020

Benvenuti F, Zanatta E, Avouac J, Müller-Ladner U, Cozzi F, Hoffmann-Vold AM, Gabrielli A, Distler O, Matucci-Cerinic M, Allanore Y, Doria A (2020)
The power of the EUSTAR cohort: key findings to date and implications for management of systemic sclerosis patients
Expert Rev Clin Immunol, 16 (11), 1065-1074
DOI 10.1080/1744666X.2021.1836962, PubMed 33076716

Distler O, Assassi S, Cottin V, Cutolo M, Danoff SK, Denton CP, Distler JHW, Hoffmann-Vold AM, Johnson SR, Müller Ladner U, Smith V, Volkmann ER, Maher TM (2020)
Predictors of progression in systemic sclerosis patients with interstitial lung disease
Eur Respir J, 55 (5)
DOI 10.1183/13993003.02026-2019, PubMed 32079645

Durheim MT, Hoffmann-Vold AM, Eagan TM, Hovden AO, Lund MB, Bjerke G, Birring SS, Jonassen TM, Johansen OE, Sjåheim T (2020)
ILD-specific health-related quality of life in systemic sclerosis-associated ILD compared with IPF
BMJ Open Respir Res, 7 (1)
DOI 10.1136/bmjresp-2020-000598, PubMed 32576559

Fretheim H, Chung BK, Didriksen H, Bækkevold ES, Midtvedt Ø, Brunborg C, Holm K, Valeur J, Tennøe AH, Garen T, Midtvedt T, Trøseid M, Zarè H, Lund MB, Hov JR, Lundin KEA, Molberg Ø, Hoffmann-Vold AM (2020)
Fecal microbiota transplantation in systemic sclerosis: A double-blind, placebo-controlled randomized pilot trial
PLoS One, 15 (5), e0232739
DOI 10.1371/journal.pone.0232739, PubMed 32437393

Fretheim H, Halse AK, Seip M, Bitter H, Wallenius M, Garen T, Salberg A, Brunborg C, Midtvedt Ø, Molberg Ø, Hoffmann-Vold AM (2020)
Multidimensional tracking of phenotypes and organ involvement in a complete nationwide systemic sclerosis cohort
Rheumatology (Oxford), 59 (10), 2920-2929
DOI 10.1093/rheumatology/keaa026, PubMed 32097470

Hoffmann-Vold AM, Allanore Y, Alves M, Brunborg C, Airó P, Ananieva LP, Czirják L, Guiducci S, Hachulla E, Li M, Mihai C, Riemekasten G, Sfikakis PP, Kowal-Bielecka O, Riccardi A, Distler O, EUSTAR collaborators (2020)
Progressive interstitial lung disease in patients with systemic sclerosis-associated interstitial lung disease in the EUSTAR database
Ann Rheum Dis, 80 (2), 219-227
DOI 10.1136/annrheumdis-2020-217455, PubMed 32988845

Hoffmann-Vold AM, Allanore Y, Bendstrup E, Bruni C, Distler O, Maher TM, Wijsenbeek M, Kreuter M (2020)
The need for a holistic approach for SSc-ILD - achievements and ambiguity in a devastating disease
Respir Res, 21 (1), 197
DOI 10.1186/s12931-020-01459-0, PubMed 32703199

Hoffmann-Vold AM, Fretheim H, Didriksen H, Molberg Ø (2020)
The potential of fecal microbiota transplantation in systemic sclerosis
Expert Rev Clin Immunol, 16 (2), 117-118
DOI 10.1080/1744666X.2019.1707665, PubMed 31858856

Hoffmann-Vold AM, Fretheim H, Meier C, Maurer B (2020)
Circulating biomarkers of systemic sclerosis - interstitial lung disease
J Scleroderma Relat Disord, 5 (2 Suppl), 41-47
DOI 10.1177/2397198319894851, PubMed 35382223

Hoffmann-Vold AM, Maher TM, Distler O (2020)
European consensus statements for interstitial lung disease in systemic sclerosis Reply
Lancet Rheumatol., 2 (6), E319-E320

Hoffmann-Vold AM, Maher TM, Philpot EE, Ashrafzadeh A, Barake R, Barsotti S, Bruni C, Carducci P, Carreira PE, Castellvi I, Del Galdo F, Distler JHW, Foeldvari I, Fraticelli P, George PM, Griffiths B, Guillen-Del-Castillo A, Hamid AM, Horvath R, Hughes M, Kreuter M, Moazedi-Fuerst F, Olas J, Paul S, Rotondo C et al. (2020)
The identification and management of interstitial lung disease in systemic sclerosis: evidence-based European consensus statements
Lancet Rheumatol., 2 (2), E71-E83
DOI 10.1016/S2665-9913(19)30144-4

Hoffmann-Vold AM, Molberg Ø (2020)
Detection, screening, and classification of interstitial lung disease in patients with systemic sclerosis
Curr Opin Rheumatol, 32 (6), 497-504
DOI 10.1097/BOR.0000000000000741, PubMed 32890027

Lemmers JM, Fretheim H, Knaapen HK, van den Hoogen FH, van Haren-Willems JH, Duijnhouwer AL, van Dijk AP, van den Ende CH, Hoffmann-Vold AM, Vonk MC (2020)
Selexipag treatment in patients with systemic sclerosis-associated pulmonary arterial hypertension in clinical practice, a case series
J Scleroderma Relat Disord, 5 (3), NP7-NP11
DOI 10.1177/2397198320916082, PubMed 35382522

Olson A, Hartmann N, Patnaik P, Wallace L, Schlenker-Herceg R, Nasser M, Richeldi L, Hoffmann-Vold AM, Cottin V (2020)
Estimation of the Prevalence of Progressive Fibrosing Interstitial Lung Diseases: Systematic Literature Review and Data from a Physician Survey
Adv Ther, 38 (2), 854-867
DOI 10.1007/s12325-020-01578-6, PubMed 33315170

Spagnolo P, Distler O, Ryerson CJ, Tzouvelekis A, Lee JS, Bonella F, Bouros D, Hoffmann-Vold AM, Crestani B, Matteson EL (2020)
Mechanisms of progressive fibrosis in connective tissue disease (CTD)-associated interstitial lung diseases (ILDs)
Ann Rheum Dis, 80 (2), 143-150
DOI 10.1136/annrheumdis-2020-217230, PubMed 33037004

Publications 2019

Distler O, Volkmann ER, Hoffmann-Vold AM, Maher TM (2019)
Current and future perspectives on management of systemic sclerosis-associated interstitial lung disease
Expert Rev Clin Immunol, 15 (10), 1009-1017
DOI 10.1080/1744666X.2020.1668269, PubMed 31566449

Elhai M, Boubaya M, Distler O, Smith V, Matucci-Cerinic M, Alegre Sancho JJ, Truchetet ME, Braun-Moscovici Y, Iannone F, Novikov PI, Lescoat A, Siegert E, Castellví I, Airó P, Vettori S, De Langhe E, Hachulla E, Erler A, Ananieva L, Krusche M, López-Longo FJ, Distler JHW, Hunzelmann N, Hoffmann-Vold AM, Riccieri V et al. (2019)
Outcomes of patients with systemic sclerosis treated with rituximab in contemporary practice: a prospective cohort study
Ann Rheum Dis, 78 (7), 979-987
DOI 10.1136/annrheumdis-2018-214816, PubMed 30967395

Elhai M, Hoffmann-Vold AM, Allanore Y (2019)
Reply
Arthritis Rheumatol, 71 (7), 1204-1206
DOI 10.1002/art.40908, PubMed 31082000

Elhai M, Hoffmann-Vold AM, Avouac J, Pezet S, Cauvet A, Leblond A, Fretheim H, Garen T, Kuwana M, Molberg Ø, Allanore Y (2019)
Performance of Candidate Serum Biomarkers for Systemic Sclerosis-Associated Interstitial Lung Disease
Arthritis Rheumatol, 71 (6), 972-982
DOI 10.1002/art.40815, PubMed 30624031

Garen T, Lerang K, Hoffmann-Vold AM, Andersson H, Midtvedt Ø, Brunborg C, Kilian K, Gudbrandsson B, Gunnarsson R, Norby G, Chaudhary A, Thoen J, Forseth KØ, Fresjar K, Førre Ø, Haugen M, Haga HJ, Gran JT, Gilboe IM, Molberg Ø, Palm Ø (2019)
Mortality and causes of death across the systemic connective tissue diseases and the primary systemic vasculitides
Rheumatology (Oxford), 58 (2), 313-320
DOI 10.1093/rheumatology/key285, PubMed 30281089

Hoffmann-Vold AM, Didriksen H, Molberg Ø (2019)
Reply
Arthritis Rheumatol, 71 (4), 655-656
DOI 10.1002/art.40816, PubMed 30663863

Hoffmann-Vold AM, Distler O, Murray B, Kowal-Bielecka O, Khanna D, Allanore Y, EUSTAR and SCTC collaborators (2019)
Setting the international standard for longitudinal follow-up of patients with systemic sclerosis: a Delphi-based expert consensus on core clinical features
RMD Open, 5 (1), e000826
DOI 10.1136/rmdopen-2018-000826, PubMed 30997150

Hoffmann-Vold AM, Fretheim H, Halse AK, Seip M, Bitter H, Wallenius M, Garen T, Salberg A, Brunborg C, Midtvedt Ø, Lund MB, Aaløkken TM, Molberg Ø (2019)
Tracking Impact of Interstitial Lung Disease in Systemic Sclerosis in a Complete Nationwide Cohort
Am J Respir Crit Care Med, 200 (10), 1258-1266
DOI 10.1164/rccm.201903-0486OC, PubMed 31310156

Hoffmann-Vold AM, Volkmann ER (2019)
Gastrointestinal involvement in systemic sclerosis: Effects on morbidity and mortality and new therapeutic approaches
J Scleroderma Relat Disord, 6 (1), 37-43
DOI 10.1177/2397198319891282, PubMed 35382247

Hoffmann-Vold AM, Weigt SS, Saggar R, Palchevskiy V, Volkmann ER, Liang LL, Ross D, Ardehali A, Lynch JP, Belperio JA (2019)
Endotype-phenotyping may predict a treatment response in progressive fibrosing interstitial lung disease
EBioMedicine, 50, 379-386
DOI 10.1016/j.ebiom.2019.10.050, PubMed 31732480

Kreuter M, Hoffmann-Vold AM (2019)
[New ways in the treatment of SSc-ILD: what makes sense?]
Z Rheumatol, 78 (9), 863-864
DOI 10.1007/s00393-019-00704-2, PubMed 31485729

Kreuter M, Hoffmann-Vold AM (2019)
New ways in the treatment of SSc-ILD: what makes sense?
Pneumologe, 16 (5), 303-304
DOI 10.1007/s10405-019-0269-z

López-Isac E, Acosta-Herrera M, Kerick M, Assassi S, Satpathy AT, Granja J, Mumbach MR, Beretta L, Simeón CP, Carreira P, Ortego-Centeno N, Castellvi I, Bossini-Castillo L, Carmona FD, Orozco G, Hunzelmann N, Distler JHW, Franke A, Lunardi C, Moroncini G, Gabrielli A, de Vries-Bouwstra J, Wijmenga C, Koeleman BPC, Nordin A et al. (2019)
GWAS for systemic sclerosis identifies multiple risk loci and highlights fibrotic and vasculopathy pathways
Nat Commun, 10 (1), 4955
DOI 10.1038/s41467-019-12760-y, PubMed 31672989

Tennøe AH, Murbræch K, Andreassen JC, Fretheim H, Midtvedt Ø, Garen T, Dalen H, Gude E, Andreassen A, Aakhus S, Molberg Ø, Hoffmann-Vold AM (2019)
Systolic Dysfunction in Systemic Sclerosis: Prevalence and Prognostic Implications
ACR Open Rheumatol, 1 (4), 258-266
DOI 10.1002/acr2.1037, PubMed 31777802

Volkmann ER, Hoffmann-Vold AM (2019)
Gastrointestinal tract microbiota modifications in systemic sclerosis
Eur J Rheumatol, 7 (Suppl 3), S228-S236
DOI 10.5152/eurjrheum.2019.19103, PubMed 31922474

Volkmann ER, Tashkin DP, Sim M, Li N, Khanna D, Roth MD, Clements PJ, Hoffmann-Vold AM, Furst DE, Kim G, Goldin J, Elashoff RM (2019)
Cyclophosphamide for Systemic Sclerosis-related Interstitial Lung Disease: A Comparison of Scleroderma Lung Study I and II
J Rheumatol, 46 (10), 1316-1325
DOI 10.3899/jrheum.180441, PubMed 30770517

Publications 2018

Hoffmann-Vold AM, Fretheim H, Midtvedt Ø, Kilian K, Angelshaug M, Chaudhary A, Gunnarsson R, Brunborg C, Garen T, Andreassen AK, Gude E, Molberg Ø (2018)
Frequencies of borderline pulmonary hypertension before and after the DETECT algorithm: results from a prospective systemic sclerosis cohort
Rheumatology (Oxford), 57 (3), 480-487
DOI 10.1093/rheumatology/kex435, PubMed 29237073

Hoffmann-Vold AM, Hesselstrand R, Fretheim H, Ueland T, Andreassen AK, Brunborg C, Palchevskiy V, Midtvedt Ø, Garen T, Aukrust P, Belperio JA, Molberg Ø (2018)
CCL21 as a Potential Serum Biomarker for Pulmonary Arterial Hypertension in Systemic Sclerosis
Arthritis Rheumatol, 70 (10), 1644-1653
DOI 10.1002/art.40534, PubMed 29687634

Hoffmann-Vold AM, Molberg Ø (2018)
CCL21 as a potential biomarker for pulmonary arterial hypertension in systemic sclerosis
Arthritis Rheumatol (in press)
DOI 10.1002/art.40740, PubMed 30281215

Hoffmann-Vold AM, Weigt SS, Palchevskiy V, Volkmann E, Saggar R, Li N, Midtvedt Ø, Lund MB, Garen T, Fishbein MC, Ardehali A, Ross DJ, Ueland T, Aukrust P, Lynch JP, Elashoff RM, Molberg Ø, Belperio JA (2018)
Augmented concentrations of CX3CL1 are associated with interstitial lung disease in systemic sclerosis
PLoS One, 13 (11), e0206545
DOI 10.1371/journal.pone.0206545, PubMed 30457999

Tennøe AH, Murbræch K, Andreassen JC, Fretheim H, Garen T, Gude E, Andreassen A, Aakhus S, Molberg Ø, Hoffmann-Vold AM (2018)
Left Ventricular Diastolic Dysfunction Predicts Mortality in Patients With Systemic Sclerosis
J Am Coll Cardiol, 72 (15), 1804-1813
DOI 10.1016/j.jacc.2018.07.068, PubMed 30286924

Wu W, Jordan S, Becker MO, Dobrota R, Maurer B, Fretheim H, Ye S, Siegert E, Allanore Y, Hoffmann-Vold AM, Distler O (2018)
Prediction of progression of interstitial lung disease in patients with systemic sclerosis: the SPAR model
Ann Rheum Dis, 77 (9), 1326-1332
DOI 10.1136/annrheumdis-2018-213201, PubMed 29875097

Publications 2017

Avouac J, Guignabert C, Hoffmann-Vold AM, Ruiz B, Dorfmuller P, Pezet S, Amar O, Tu L, Van Wassenhove J, Sadoine J, Launay D, Elhai M, Cauvet A, Subramaniam A, Resnick R, Hachulla E, Molberg Ø, Kahan A, Humbert M, Allanore Y (2017)
Role of Stromelysin 2 (Matrix Metalloproteinase 10) as a Novel Mediator of Vascular Remodeling Underlying Pulmonary Hypertension Associated With Systemic Sclerosis
Arthritis Rheumatol, 69 (11), 2209-2221
DOI 10.1002/art.40229, PubMed 28805015

Bossini-Castillo L, Campillo-Davó D, López-Isac E, Carmona FD, Simeon CP, Carreira P, Callejas-Rubio JL, Castellví I, Fernández-Nebro A, Rodríguez-Rodríguez L, Rubio-Rivas M, García-Hernández FJ, Madroñero AB, Beretta L, Santaniello A, Lunardi C, Airó P, Hoffmann-Vold AM, Kreuter A, Riemekasten G, Witte T, Hunzelmann N, Vonk MC, Voskuyl AE, de Vries-Bouwstra J et al. (2017)
An MIF Promoter Polymorphism Is Associated with Susceptibility to Pulmonary Arterial Hypertension in Diffuse Cutaneous Systemic Sclerosis
J Rheumatol, 44 (10), 1453-1457
DOI 10.3899/jrheum.161369, PubMed 28668810

Hoffmann-Vold AM, Midtvedt Ø, Tennøe AH, Garen T, Lund MB, Aaløkken TM, Andreassen AK, Elhage F, Brunborg C, Taraldsrud E, Molberg Ø (2017)
Cardiopulmonary Disease Development in Anti-RNA Polymerase III-positive Systemic Sclerosis: Comparative Analyses from an Unselected, Prospective Patient Cohort
J Rheumatol, 44 (4), 459-465
DOI 10.3899/jrheum.160867, PubMed 28089974

Volkmann ER, Hoffmann-Vold AM, Chang YL, Jacobs JP, Tillisch K, Mayer EA, Clements PJ, Hov JR, Kummen M, Midtvedt Ø, Lagishetty V, Chang L, Labus JS, Molberg Ø, Braun J (2017)
Systemic sclerosis is associated with specific alterations in gastrointestinal microbiota in two independent cohorts
BMJ Open Gastroenterol, 4 (1), e000134
DOI 10.1136/bmjgast-2017-000134, PubMed 28761687

Volkmann ER, Tashkin DP, Li N, Roth MD, Khanna D, Hoffmann-Vold AM, Kim G, Goldin J, Clements PJ, Furst DE, Elashoff RM (2017)
Mycophenolate Mofetil Versus Placebo for Systemic Sclerosis-Related Interstitial Lung Disease: An Analysis of Scleroderma Lung Studies I and II
Arthritis Rheumatol, 69 (7), 1451-1460
DOI 10.1002/art.40114, PubMed 28376288

Publications 2016

Elhai M, Avouac J, Hoffmann-Vold AM, Ruzehaji N, Amiar O, Ruiz B, Brahiti H, Ponsoye M, Fréchet M, Burgevin A, Pezet S, Sadoine J, Guilbert T, Nicco C, Akiba H, Heissmeyer V, Subramaniam A, Resnick R, Molberg Ø, Kahan A, Chiocchia G, Allanore Y (2016)
OX40L blockade protects against inflammation-driven fibrosis
Proc Natl Acad Sci U S A, 113 (27), E3901-10
DOI 10.1073/pnas.1523512113, PubMed 27298374

Hoffmann-Vold AM, Tennøe AH, Garen T, Midtvedt Ø, Abraityte A, Aaløkken TM, Lund MB, Brunborg C, Aukrust P, Ueland T, Molberg Ø (2016)
High Level of Chemokine CCL18 Is Associated With Pulmonary Function Deterioration, Lung Fibrosis Progression, and Reduced Survival in Systemic Sclerosis
Chest, 150 (2), 299-306
DOI 10.1016/j.chest.2016.03.004, PubMed 26997242

Molberg Ø, Hoffmann-Vold AM (2016)
Interstitial lung disease in systemic sclerosis: progress in screening and early diagnosis
Curr Opin Rheumatol, 28 (6), 613-8
DOI 10.1097/BOR.0000000000000323, PubMed 27387267

Publications 2015

Hoffmann-Vold AM (2015)
Dr. Hoffmann-Vold replies
J Rheumatol, 42 (12), 2513
DOI 10.3899/jrheum.150886, PubMed 26628710

Hoffmann-Vold AM, Aaløkken TM, Lund MB, Garen T, Midtvedt Ø, Brunborg C, Gran JT, Molberg Ø (2015)
Predictive value of serial high-resolution computed tomography analyses and concurrent lung function tests in systemic sclerosis
Arthritis Rheumatol, 67 (8), 2205-12
DOI 10.1002/art.39166, PubMed 25916462

Reiseter S, Molberg Ø, Gunnarsson R, Lund MB, Aalokken TM, Aukrust P, Ueland T, Garen T, Brunborg C, Michelsen A, Abraityte A, Hoffmann-Vold AM (2015)
Associations between circulating endostatin levels and vascular organ damage in systemic sclerosis and mixed connective tissue disease: an observational study
Arthritis Res Ther, 17, 231
DOI 10.1186/s13075-015-0756-5, PubMed 26315510

Publications 2014

Bergersen TK, Hoffmann-Vold AM, Midtvedt Ø, Gran JT, Mørk C, Toska K, Elstad M (2014)
Dysfunctional arteriovenous anastomoses in hands of systemic sclerosis patients with digital ulcers
Clin Exp Rheumatol, 32 (6 Suppl 86), S-53-9
PubMed 24847906

Hoffmann-Vold AM, Gunnarsson R, Garen T, Midtvedt Ø, Molberg Ø (2014)
Performance of the 2013 American College of Rheumatology/European League Against Rheumatism Classification Criteria for Systemic Sclerosis (SSc) in large, well-defined cohorts of SSc and mixed connective tissue disease
J Rheumatol, 42 (1), 60-3
DOI 10.3899/jrheum.140047, PubMed 25274890

Publications 2013

Hoffmann-Vold AM, Molberg Ø, Midtvedt Ø, Garen T, Gran JT (2013)
Survival and causes of death in an unselected and complete cohort of Norwegian patients with systemic sclerosis
J Rheumatol, 40 (7), 1127-33
DOI 10.3899/jrheum.121390, PubMed 23637316

Publications 2012

Bossini-Castillo L, Martin JE, Broen J, Simeon CP, Beretta L, Gorlova OY, Vonk MC, Ortego-Centeno N, Espinosa G, Carreira P, García de la Peña P, Oreiro N, Román-Ivorra JA, Castillo MJ, González-Gay MA, Sáez-Comet L, Castellví I, Schuerwegh AJ, Voskuyl AE, Hoffmann-Vold AM, Hesselstrand R, Nordin A, Lunardi C, Scorza R, van Laar JM et al. (2012)
Confirmation of TNIP1 but not RHOB and PSORS1C1 as systemic sclerosis risk factors in a large independent replication study
Ann Rheum Dis, 72 (4), 602-7
DOI 10.1136/annrheumdis-2012-201888, PubMed 22896740

Bossini-Castillo L, Simeon CP, Beretta L, Broen JC, Vonk MC, Ríos-Fernández R, Espinosa G, Carreira P, Camps MT, Castillo MJ, González-Gay MA, Beltrán E, Carmen Freire Md, Narváez J, Tolosa C, Witte T, Kreuter A, Schuerwegh AJ, Hoffmann-Vold AM, Hesselstrand R, Lunardi C, van Laar JM, Chee MM, Herrick A, Koeleman BP et al. (2012)
A multicenter study confirms CD226 gene association with systemic sclerosis-related pulmonary fibrosis
Arthritis Res Ther, 14 (2), R85
DOI 10.1186/ar3809, PubMed 22531499

Diaz-Gallo LM, Simeon CP, Broen JC, Ortego-Centeno N, Beretta L, Vonk MC, Carreira PE, Vargas S, Román-Ivorra JA, González-Gay MA, Tolosa C, López-Longo FJ, Espinosa G, Vicente EF, Hesselstrand R, Riemekasten G, Witte T, Distler JH, Voskuyl AE, Schuerwegh AJ, Shiels PG, Nordin A, Padyukov L, Hoffmann-Vold AM, Scorza R et al. (2012)
Implication of IL-2/IL-21 region in systemic sclerosis genetic susceptibility
Ann Rheum Dis, 72 (7), 1233-8
DOI 10.1136/annrheumdis-2012-202357, PubMed 23172754

Hoffmann-Vold AM, Midtvedt Ø, Molberg Ø, Garen T, Gran JT (2012)
Prevalence of systemic sclerosis in south-east Norway
Rheumatology (Oxford), 51 (9), 1600-5
DOI 10.1093/rheumatology/kes076, PubMed 22539477

Publications 2011

Bossini-Castillo L, Simeon CP, Beretta L, Vonk MC, Callejas-Rubio JL, Espinosa G, Carreira P, Camps MT, Rodríguez-Rodríguez L, Rodríguez-Carballeira M, García-Hernández FJ, López-Longo FJ, Hernández-Hernández V, Sáez-Comet L, Egurbide MV, Hesselstrand R, Nordin A, Hoffmann-Vold AM, Vanthuyne M, Smith V, De Langhe E, Kreuter A, Riemekasten G, Witte T, Hunzelmann N et al. (2011)
Confirmation of association of the macrophage migration inhibitory factor gene with systemic sclerosis in a large European population
Rheumatology (Oxford), 50 (11), 1976-81
DOI 10.1093/rheumatology/ker259, PubMed 21875883

Carmona FD, Simeon CP, Beretta L, Carreira P, Vonk MC, Ríos-Fernández R, Espinosa G, Navarrete N, Vicente-Rabaneda E, Rodríguez-Rodríguez L, Tolosa C, García-Hernández FJ, Castellví I, Egurbide MV, Fonollosa V, González-Gay MA, Rodríguez-Carballeira M, Díaz-Gónzalez F, Sáez-Comet L, Hesselstrand R, Riemekasten G, Witte T, Voskuyl AE, Schuerwegh AJ, Madhok R et al. (2011)
Association of a non-synonymous functional variant of the ITGAM gene with systemic sclerosis
Ann Rheum Dis, 70 (11), 2050-2
DOI 10.1136/ard.2010.148874, PubMed 21571730

Gorlova O, Martin JE, Rueda B, Koeleman BP, Ying J, Teruel M, Diaz-Gallo LM, Broen JC, Vonk MC, Simeon CP, Alizadeh BZ, Coenen MJ, Voskuyl AE, Schuerwegh AJ, van Riel PL, Vanthuyne M, van 't Slot R, Italiaander A, Ophoff RA, Hunzelmann N, Fonollosa V, Ortego-Centeno N, González-Gay MA, García-Hernández FJ, González-Escribano MF et al. (2011)
Identification of novel genetic markers associated with clinical phenotypes of systemic sclerosis through a genome-wide association strategy
PLoS Genet, 7 (7), e1002178
DOI 10.1371/journal.pgen.1002178, PubMed 21779181

Publications 2010

Radstake TR, Gorlova O, Rueda B, Martin JE, Alizadeh BZ, Palomino-Morales R, Coenen MJ, Vonk MC, Voskuyl AE, Schuerwegh AJ, Broen JC, van Riel PL, van 't Slot R, Italiaander A, Ophoff RA, Riemekasten G, Hunzelmann N, Simeon CP, Ortego-Centeno N, González-Gay MA, González-Escribano MF, Spanish Scleroderma Group, Airo P, van Laar J, Herrick A et al. (2010)
Genome-wide association study of systemic sclerosis identifies CD247 as a new susceptibility locus
Nat Genet, 42 (5), 426-9
DOI 10.1038/ng.565, PubMed 20383147

Publications 2006

Flatø B, Hoffmann-Vold AM, Reiff A, Førre Ø, Lien G, Vinje O (2006)
Long-term outcome and prognostic factors in enthesitis-related arthritis: a case-control study
Arthritis Rheum, 54 (11), 3573-82
DOI 10.1002/art.22181, PubMed 17075863